Şiddetli Anti-CV2/CRMP5, Anti-Hu ve Anti-SOX1 Anti-Vücut-Pozitif Paraneoplastik Nörolojik Sendrom Atezolizumab Tedavisinde Tümör Tekrarı ile İlişkilidir.

Araştırma özeti

Aşağıdaki metin kaynak makalenin lisansı doğrulanmış orijinal özetidir. cc by

We report a case of an 80-year-old man with small-cell lung cancer who developed paraneoplastic neurological syndrome (PNS) after four years of immune checkpoint inhibitor (ICI) therapy (atezolizumab). The patient presented with bilateral optic neuropathy, parkinsonism, and truncal ataxia. MRI revealed lesions in the basal ganglia and medial temporal lobes. Serological testing revealed a marked elevation of tumor markers, along with the presence of anti-CV2/CRMP5, anti-Hu, and anti-SOX1 antibodies. PNS onset may be primarily triggered by tumor recurrence, with long-term ICI exposure further amplifying the underlying immune response.

İlgili konular